SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Litecoin is a peer-to-peer cryptocurrency created by Charlie Lee. It was created based on the Bitcoin protocol but differs in terms of the hashing algorithm used. Litecoin uses the memory intensive Scrypt proof of work mining algorithm. Scrypt allows consumer-grade hardware such as GPU to mine those coins.  Why Litecoin? Litecoin is a cryptocurrency that has evolved from Bitcoin after its own popularity in the industry, this alternative, or ‘altcoin’ has emerged to allow investors to diversify their digital currency package, according to Investopedia. Litecoin is one of the most prominent altcoins and was created by former Google employee and Director of Engineering at Coinbase, Charlie Lee. Litecoin was the first to alter Bitcoin and the most significant difference is that it takes 2.5 minutes for Litecoin to generate a block, or transaction, in comparison to Bitcoin's 10 minutes.  ‘While this matters little to traders, miners who use hardware to run Bitcoin's network cannot switch over to Litecoin. This keeps bigger mining conglomerates away from Litecoin because they cannot easily optimize their profits by swapping to another coin, contributing to a more decentralized experience. Litecoin also has bigger blocks, and more coins in circulation, making it more affordable and swift when transacting,’ Investopedia explained.  As explained above, Litecoin can transact a lot faster than Bitcoin, but there are also a number of other characteristics that investors need to know before trading. Litecoin can handle higher volumes of transactions because of the capability of transacting faster and if Bitcoin attempted to transact on the scale of its altcoin, a code update would be needed. However, Litecoin’s blocks would be larger, but with more ‘orphaned blocks'. The faster block time of litecoin reduces the risk of double spending attacks - this is theoretical in the case of both networks having the same hashing power.  Litecoin Technical Details: The transaction confirmation time taken for Litecoin is about 2.5 minutes on average (as compared to Bitcoin's 10 minutes). The Litecoin network is scheduled to cap at 84 million currency units.   Litecoin has inspired many other popular alternative currencies (eg. Dogecoin) because of its Scrypt hashing algorithm in order to prevent ASIC miners from mining those coins. However it is said that by the end of this year, Scrypt ASIC will enter the mass market.

Litecoin

Litecoin is actively trending, with its community demonstrating strong conviction and calling to 'hold' amidst current market volatility, anticipating a significant breakout. Many perceive it as 'digital silver' poised for substantial long-term growth, with discussions highlighting its foundational role and developments like LitVM and Omnichain features for earning yield.

BlackRock Institutional Trust Company N.A. - iShares Silver Trust

iShares Silver Trust

Ongoing CME margin hikes and impending Chinese export restrictions are driving significant volatility and intense debate around SLV. The community is sharply divided between those anticipating a continued silver squeeze fueled by industrial demand and those fearing market manipulation and a potential sharp pullback in the highly contested paper market.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending as investors anticipate a potential rebound with the close of year-end tax loss selling, coupled with ongoing speculation about Elon Musk's future actions regarding X payments. The community shows a strong divide, with many asserting its status as the 'King meme coin' and envisioning significant price appreciation, while others express skepticism about its immediate trajectory.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is trending due to significant year-end tax loss harvesting and persistent selling pressure from initial SPAC investors, which continues to drive down its share price. The community is sharply divided; bulls emphasize the company's profitability and international growth potential as a long-term accumulation opportunity, drawing comparisons to early fintech successes. Conversely, bears highlight ongoing dilution and concerns over the stock's performance, questioning its fundamental value.

Vanda Pharmaceuticals, Inc. engages in the development and commercialization of therapies for high unmet medical needs. The firm intends to treat schizophrenia, jet lag disorder, atopic dermatitis, central nervous system disorders, and circadian rhythm sleep disorder. Its product portfolio includes HETLIOZ, Fanapt, Tradipitant, Trichostatin, and AQW051. The company was founded by Mihael Hristos Polymeropoulos and Argeris N. Karabelas in 2002 and is headquartered in Washington, DC.

Vanda Pharmaceuticals Inc

Vanda Pharmaceuticals is trending after receiving FDA approval for NEREUS, its motion sickness drug, marking the first new medication in this category in nearly 40 years. The community is highly optimistic, anticipating its significant potential to address GLP-1 associated nausea and sparking strong speculation of a major pharmaceutical buyout. With several additional pipeline catalysts on the horizon, many view the stock as deeply undervalued and poised for substantial future upside.

RAGE GUY (RAGE) is a cryptocurrency inspired by the Rage Guy meme, one of the earliest and most recognizable characters from internet rage comics. The project captures the cultural legacy of early meme history and brings it onto the blockchain in tokenized form. It is designed as a community-driven digital asset that celebrates internet culture, nostalgia, and the role memes play in shaping online communities.

Rage Guy

RAGE CRYPTO is trending due to its exceptionally active and dedicated community, passionately championing the 'OG meme' narrative of Rage Comics. This committed base is consistently developing an ecosystem with tools like RageMaker and RageGames, aiming to onboard new users into crypto while expressing strong conviction for significant long-term growth and widespread recognition. The community is focused on leading a 'return to the memes' within the broader market, viewing RAGE as fundamentally undervalued and destined for future success.

MannKind Corp. is a biopharmaceutical company, which focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases. Its products and pipeline include Afrezza, Pediatric Afrezza, V-Go, Tyvaso DPI, MNKD-101, MNKD-201, MNKD-301, and MNKD-501. The company was founded by Alfred E. Mann on February 14, 1991 and is headquartered in Danbury, CT.

Mannkind Corp

Mannkind Corp is trending following the recent FDA approval of FUROSCIX for pediatric use and new patents issued for its ReadyFlow Autoinjector, which the community views as a significant advancement for at-home fluid management. While optimism surrounds these developments and the anticipated Afrezza launch in India, a persistent debate centers on current management's ability to translate product success into substantial long-term shareholder value.

Ekso Bionics Holdings, Inc. engages in the provision of design, development, and sale of exoskeleton technology that currently has applications in healthcare and industrial markets. The company was founded on January 30, 2012 and is headquartered in San Rafael, CA.

Ekso Bionics Holdings Inc

Ekso Bionics is surging with immense trading volume following news of a proposed business combination with Applied Digital's cloud division, forming an AI compute platform called ChronoScale. This pivot into AI infrastructure, combined with the stock's low float, is driving aggressive price action and high price targets among community members. However, some discussions highlight potential significant dilution for existing shareholders, creating a divided outlook on its long-term implications amidst the short-term volatility.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding is trending due to its recent loan agreement, which aims to secure capital without immediate equity dilution, and the planned distribution of a "Dream Bowl 2026 Meme Coin" dividend tied to its Datavault AI partnership. Community sentiment is highly polarized: many foresee a significant short squeeze and value creation from tokenization and potential asset sales, while a vocal segment views these developments as further distractions by a management team perceived as eroding shareholder value. The broader context involves the company's foray into AI-driven Real-World Asset tokenization, alongside ongoing scrutiny of its core biotech pipeline.

iShares Bitcoin Trust ETF - iShares Bitcoin Trust Beneficial Interest

iShares Bitcoin ETF

IBIT is trending amid notable Bitcoin volatility and a mixed outlook driven by fluctuating ETF inflows and the impending Bank of Japan rate decision. The community is sharply divided between those anticipating a prolonged 'crypto winter' and others who see the current dips as a prime 'buy the dip' opportunity driven by continued whale accumulation and institutional interest. This divergence in sentiment underscores the ongoing debate about Bitcoin's predictable cyclical behavior versus its increasing integration into traditional finance through instruments like IBIT.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Eli Lilly vs. Merck: Which Drug Giant Appears Better Poised Today?

LLY's explosive growth from Mounjaro and Zepbound outpaces MRK's Keytruda-led gains, despite valuation concerns.

BMO downgrades Verve Therapeutics saying Lilly buyout deal caps upside

Investing.com -- BMO Capital Markets downgraded Verve Therapeutics to Market perform, saying Eli Lilly’s agreement to buy the gene-editing specialist leaves limited room for the stock to rise before the transaction is expected to close in the third quarter of 2025.

Gene-Editing Stocks Gain on LLY-VERV Deal Announcement 

Shares of Verve Therapeutics, Inc. (VERV) rocketed 75% in pre-market on Tuesday after Eli Lilly and Company (LLY) <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.lilly.com/news-releases/news-release-details/lilly-acquire-verve-therapeutics-advance-one-time-treatments">announced</a> its intent to acquire the company for up to $1.3 billion.Verve is developing gene editing medicines designed to address the drivers of atherosclerotic cardiovascular disease (ASCVD), such as low-density lipoproteins, triglyceride-rich lipoproteins, and lipoprotein(a), through treatments that may only need to be given once in a lifetime.Under the terms of the deal, Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones. The aggregate value of the deal is approximately $1.3 billion.The upfront purchase price of $10.50 represents a premium of over 67% to Verve’s closing price on Monday.The transaction is expected to close in the third quarter, subject to customary closing conditions.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/VERV">VERV</a> jumped from ‘bearish’ to ‘extremely bullish’ territory over the past 24 hours while message volume rose from ‘normal’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1262/134;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_18_59_AM_png_4e0f45260c.webp" alt="VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1262" height="134"><figcaption>VERV's Sentiment Meter and Message Volume as of 8:20 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user, however, opined that the offer seems low.<stembedurl>https://stocktwits.com/XavierXV/message/618132279</stembedurl>Another user believes that the offer is ‘terrible’ for long-term shareholders while being great news for those who bought it recently.<stembedurl>https://stocktwits.com/PensionPulse/message/618129981</stembedurl> Meanwhile, sentiment around <a href="https://stocktwits.com/symbol/LLY">LLY</a> stayed unchanged within ‘neutral’ territory, coupled with ‘normal’ message volume.<figure class="image"><img style="aspect-ratio:1268/142;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_17_at_8_21_01_AM_png_80a8da75d9.webp" alt="LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits" width="1268" height="142"><figcaption>LLY's Sentiment Meter and Message Volume as of 8:25 a.m. ET on June 17, 2025 | Source: Stocktwits</figcaption></figure>Both LLY and VERV stocks are up by about 4% this year.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/wells-fargo-expects-tesla-deliveries-to-dip-further-in-2025/chlYvypRRTv">Wells Fargo Expects Tesla Deliveries To Dip Further In 2025, But Retail Says Downward Trend Is Over</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

Verve Therapeutics Stock Rockets 75% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B: Retail Says Offer Is ‘Low’

Lilly will acquire all outstanding shares of Verve for $10.50 per share in cash payable at closing, in addition to a contingent value right (CVR) per share that entitles holders to $3 per share, subject to the completion of certain milestones.

Verve Therapeutics Stock Rockets 76% Pre-Market After Eli Lilly Agrees To Acquire The Company For Up To $1.3B

Equity

Eli Lilly is in late-stage talks to purchase Verve Therapeutics in a transaction that could total $1.3 billion, according to a&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.ft.com/content/53d021c9-d15f-4471-86ef-e9abfc3ae7db">report</a> by the Financial Times.Verve Therapeutics surged 74.8% after hours to $10.96 following takeover speculation, while Eli Lilly slipped 1.4% to $807.58 during regular trade.The deal features an upfront payment of nearly $1 billion and an additional $300 million, contingent upon clinical results, which would double Verve Therapeutics' current market value to $559 million.Verve is advancing gene-editing treatments for high cholesterol and&nbsp;has disclosed positive Phase 1 findings for its primary drug candidate.&nbsp;The company already has a partnership with Eli Lilly.If completed, the deal would extend Lilly’s focus on early-stage innovation rather than commercial-stage assets — a strategy backed by its financial strength from diabetes and obesity blockbusters Mounjaro and Zepbound, projected to generate over $30 billion this year.Lilly’s potential move comes amid renewed biopharma dealmaking after a subdued period.Recent deals include Sanofi’s $9.5 billion tie-up with Blueprint Medicines and Bristol Myers Squibb’s $11.1 billion collaboration with BioNTech.&nbsp;The Verve deal will reportedly be announced later this week, barring any last-minute changes.On Stocktwits, retail sentiment for Eli Lilly was ‘neutral’ with ‘normal’ message volume, while Verve Therapeutics saw ‘extremely bullish’ sentiment amid ‘extremely high’ message volume.Eli Lilly’s stock has risen 3.8% so far in 2025, while Verve Therapeutics’ stock has gained 4.3%For updates and corrections, email newsroom[at]stocktwits[dot]com.

A sign with the company logo sits outside of the headquarters campus of Eli Lilly and Company on March 17, 2024 in Indianapolis, Indiana. (Photo by Scott Olson/Getty Images)

Verve Therapeutics Soars 75% After-Hours Following Report Of $1.3B Eli Lilly Takeover Talks

The deal would double Verve’s market value and expand Lilly’s pipeline of early-stage therapies.

Eli Lilly close to buying gene editing firm Verve for $1.3 bln- FT

Investing.com-- Eli Lilly and Company (NYSE:LLY) is in advanced talks to buy gene editing start-up  Verve Therapeutics  Inc (NASDAQ:VERV), the Financial Times reported on Monday, as the world’s biggest drugmaker seeks to increase its pipeline of experimental drugs. 

What Makes Verve Therapeutics (VERV) a New Buy Stock

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?

3 Top Genomics Stocks to Add to Your Portfolio in 2025

Verve Therapeutics, Inc. is a genetic medicines company, which engages in the development of approach to the care of cardiovascular diseases. The company was founded by Burt A. Adelman, Keith J. Joung, Sekar Kathiresan, Kiran Musunuru, Anthony Philippakis, Issi Rozen, and Barry Ticho in 2018 and is headquartered in Boston, MA.

VERV
Verve Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest VERV News

VERVVerve Therapeutics Inc